Evidence map›Paper›PMID 32956405›Full record

ArticlePLoS pathogens2020

NLRX1 is a key regulator of immune signaling during invasive pulmonary aspergillosis.

Bridget Kastelberg, Nuria Tubau-Juni, Tariq Ayubi, Austin Leung, Andrew Leber, Raquel Hontecillas, Josep Bassaganya-Riera, Shiv D Kale

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  6. Mgl2Nature communications · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Focusing on the Cell Type Specific Regulatory Actions of NLRX1.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
  17. Behind the Scenes: Nod-Like Receptor X1 Controls Inflammation and Metabolism.Frontiers in cellular and infection microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bridget KastelbergNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.ORCID 0000-0002-6039-5898
Nuria Tubau-JuniNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.ORCID 0000-0002-5787-8055
Tariq AyubiNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.ORCID 0000-0001-7233-9749
Austin LeungNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.ORCID 0000-0002-8394-4212
Andrew LeberNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.
Raquel HontecillasNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.
Josep Bassaganya-RieraNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.
Shiv D KaleNutritional Immunology and Molecular Medicine Institute, Blacksburg, Virginia, United States of America.ORCID 0000-0002-0645-1799

Funding

How Does Nlrx1 regulate fungal killing and immune signaling during pulmonary infectionR21AI149280 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI KALE, SHIV DUTT · 2020 to 2020
$240k
NIAID NIH HHS R21 AI149280
6 · The paper itself

Abstract

Aspergillus fumigatus is an opportunistic fungal pathogen of immunocompromised patient populations. Mortality is thought to be context-specific and occurs via both enhanced fungal growth and immunopathogenesis. NLRX1 is a negative regulator of immune signaling and metabolic pathways implicated in host responses to microbes, cancers, and autoimmune diseases. Our study indicates loss of Nlrx1 results in enhanced fungal burden, pulmonary inflammation, immune cell recruitment, and mortality across immuno-suppressed and immuno-competent models of IPA using two clinically derived isolates (AF293, CEA10). We observed that the heightened mortality is due to enhanced recruitment of CD103+ dendritic cells (DCs) that produce elevated amounts of IL-4 resulting in a detrimental Th2-mediated immune response. Adoptive transfer of Nlrx1-/- CD103+ DCs in neutropenic NRG mice results in enhanced mortality that can be ablated using IL-4 neutralizing antibodies. In vitro analysis of CD103+ DCs indicates loss of Nlrx1 results in enhanced IL-4 production via elevated activation of the JNK/JunB pathways. Interestingly, loss of Nlrx1 also results in enhanced recruitment of monocytes and neutrophils. Chimeras of irradiated Nlrx1-/- mice reconstituted with wild type bone marrow have enhanced neutrophil recruitment and survival during models of IPA. This enhanced immune cell recruitment in the absence of Nlrx1 is mediated by excessive production of CXCL8/IL-8 family of chemokines and IL-6 via early and enhanced activation of P38 in response to A. fumigatus conidia as shown in BEAS-2B airway epithelial cells. In summary, our results point strongly towards the cell-specific and contextual function of Nlrx1 during invasive pulmonary aspergillosis and may lead to novel therapeutics to reduce Th2 responses by CD103+ DCs or heightened recruitment of neutrophils.

Indexed as

AnimalsAspergillus fumigatusCell LineCytokinesDendritic CellsMAP Kinase Kinase 4MAP Kinase Signaling SystemMiceMice, KnockoutMitochondrial ProteinsNeutrophilsp38 Mitogen-Activated Protein KinasesPulmonary AspergillosisTh2 CellsTranscription FactorsCytokinesJunB protein, mouseMAP Kinase Kinase 4Mitochondrial ProteinsNLRX1 protein, mousep38 Mitogen-Activated Protein KinasesTranscription Factors

Identifiers

PMID32956405
PMCPMC7529209
OpenAlexW3087347161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.